One of the pioneers of mRNA technologies, BioNTech (Nasdaq: BNTX), is investing the proceeds of its work during the pandemic on its original focus - cancer vaccines.
A major new agreement with the UK government will see the company accelerating clinical trials for personalized mRNA immunotherapies in the country.
BioNTech is the company behind the Comirnaty vaccine, a breakthrough product responsible for saving millions of lives while generating tens of billions in revenue for the German firm and its partner, US pharma giant Pfizer (NYSE: PFE).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze